Skip to Primary Navigation

PMCPA concludes Gossamer Bio pre-license promotion breach investigation

Open medication bottle with green capsules
Photo: Spencer Platt/Getty Images

The UK watchdog found the biopharma company did not comply with two clauses of the AMPI Code related to a seralutinib meeting display.

The UK’s Prescription Medicines Code of Practice Authority (PMCPA) issued the final resolution in its case pertaining to the nature of Gossamer Bio’s presence at a meeting for healthcare professionals.

The PMCPA case summary relates to multiple complaints allegedly in violation of the Association of the British Pharmaceutical